Significant Survival Benefit15 Jul 2025 12:27
I don't think people have grasped how big the news is yet, but the sp will soon reflect as smart ones are loading up.
Read and read again
The trial demonstrated a significant survival benefit with (immune checkpoint inhibitor) avelumab maintenance plus best supportive care (BSC) versus BSC alone. EpiSwitch blood-based biomarkers were evaluated on their association with tumour profiles and their immunophenotype, related to high and low immunogenic response.
The researchers conclude that EpiSwitch blood testing can effectively determine whether a tumour has high or low immune activity, which is an important factor in making informed cancer treatment decisions. The EpiSwitch technology provides accurate insights into the body's immune response to the cancer in a less invasive manner than traditional tissue biopsies. The ability to utilise this technology to identify which patients are most likely to benefit from specific treatment options represents a significant advancement in patient care.